Eyby Leon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eyby Leon has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Jullianne Diaz
Children's National Medical Center and George Washington University, Washington, DC
7 shared publications- Seth I. Berger
Resarch and Development, Ambry Genetics, Aliso Viejo, CA
3 shared publications - Ilana Miller
Division of Genetics, Children’s National Hospital, Washington, USA
2 shared publications - Jullianne Diaz
Department of Genetics and Metabolism, Children's National Hospital, Washington, DC 20010, USA
2 shared publications - Youssef A. Kousa
Division of Neurology, Children’s National Hospital, Washington, DC 20010, USA
2 shared publications Aleksander Milosavljevic
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
Death Secondary to Brain Herniation in Classic MSUD Patients: A Case Series From One Center
Maple Syrup Urine Disease (MSUD) is an inborn error of metabolism associated with defects in the branched‐chain alpha‐keto acid dehydrogenase complex. Despite careful management, patients may experience metabolic decompensation, elevation of leucine levels, cerebral edema, brain herniation, and death. Two populations have been reported to be the most affected: Mennonite and Ashkenazi Jewish. There are three genes associated with this condition, with DBT being the least frequently involved and usually associated with milder or thiamine‐responsive MSUD. We present four patients, three of Salvadoran and one of Afghan ancestry, diagnosed with classic MSUD who developed cerebral edema, herniated, and died despite aggressive medical management. All patients had pathogenic variants in the DBT gene and were not thiamine‐responsive. They all presented with elevated plasma leucine levels that were not their highest recorded after diagnosis. Decompensation in an MSUD patient should be approached with extreme caution, considering that brain edema can progress very rapidly to brain herniation and death, especially since there are no reliable biochemical markers that can predict this fatal outcome. The phenotype and genotype of classic MSUD need to be described more thoroughly, since they can have a more severe presentation and higher mortality rate than previously reported and might be misleading to the treating clinician when genetic testing results are of uncertain significance. Our cohort presents four patients of non‐Mennonite or Ashkenazi Jewish descent with fatal brain herniation occurring rapidly without being preceded by their highest plasma leucine peak registered, significant ketonuria, elevated anion gap, and/or hyponatremia on admission. This highlights the importance of studying different populations affected by MSUD and considering liver transplantation as the potential best treatment option for certain patients.
- 13 November 2026
- Published by Wiley in JIMD Reports
- Vol. 67 (6)
Open AccessDeath Secondary to Brain Herniation in Classic MSUD Patients: A Case Series From One Center
Maple Syrup Urine Disease (MSUD) is an inborn error of metabolism associated with defects in the branched‐chain alpha‐keto acid dehydrogenase complex. Despite careful management, patients may experience metabolic decompensation, elevation of leucine levels, cerebral edema, brain herniation, and death. Two populations have been reported to be the most affected: Mennonite and Ashkenazi Jewish. There are three genes associated with this condition, with DBT being the least frequently involved and usually associated with milder or thiamine‐responsive MSUD. We present four patients, three of Salvadoran and one of Afghan ancestry, diagnosed with classic MSUD who developed cerebral edema, herniated, and died despite aggressive medical management. All patients had pathogenic variants in the DBT gene and were not thiamine‐responsive. They all presented with elevated plasma leucine levels that were not their highest recorded after diagnosis. Decompensation in an MSUD patient should be approached with extreme caution, considering that brain edema can progress very rapidly to brain herniation and death, especially since there are no reliable biochemical markers that can predict this fatal outcome. The phenotype and genotype of classic MSUD need to be described more thoroughly, since they can have a more severe presentation and higher mortality rate than previously reported and might be misleading to the treating clinician when genetic testing results are of uncertain significance. Our cohort presents four patients of non‐Mennonite or Ashkenazi Jewish descent with fatal brain herniation occurring rapidly without being preceded by their highest plasma leucine peak registered, significant ketonuria, elevated anion gap, and/or hyponatremia on admission. This highlights the importance of studying different populations affected by MSUD and considering liver transplantation as the potential best treatment option for certain patients.
- 26 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Third Patient With Biallelic Variants in SMAD6 With an Overlapping Phenotype: Developmental Delays, Dysmorphic Features, and Cardiovascular Abnormalities
SMAD6 encodes an inhibitory SMAD protein that modulates BMP and TGF‐β signaling. Heterozygous pathogenic variants in SMAD6 have been primarily associated with aortic valve disease, radioulnar synostosis, and nonsyndromic sagittal and metopic synostosis. However, only two syndromic patients with biallelic variants have been reported in the literature. We report a 4‐year‐old girl with neurodevelopmental delays, dysmorphic features, complex congenital heart disease, renal asymmetry, and arterial tortuosity. Whole exome sequencing showed two homozygous SMAD6 variants of uncertain significance: c.161G>T (p.Gly54Val) and c.1A>G (p.Met1?). This is the third patient with biallelic SMAD6 variants associated with skeletal changes, more complex cardiovascular phenotype, facial dysmorphism, and novel arterial abnormalities. This suggests biallelic variants may cause a distinct and potentially more severe autosomal recessive syndrome. Functional investigation is needed to determine the molecular consequences of biallelic SMAD6 variants and to inform variant classification and mechanism. This report characterizes a potential unique genetic syndrome associated with biallelic SMAD6 variants, highlighting the importance of additional sequencing, vascular imaging, and multidisciplinary care coordination for these patients.
- 26 August 2026
- Published by Wiley in American Journal of Medical Genetics Part A
Third Patient With Biallelic Variants in SMAD6 With an Overlapping Phenotype: Developmental Delays, Dysmorphic Features, and Cardiovascular Abnormalities
SMAD6 encodes an inhibitory SMAD protein that modulates BMP and TGF‐β signaling. Heterozygous pathogenic variants in SMAD6 have been primarily associated with aortic valve disease, radioulnar synostosis, and nonsyndromic sagittal and metopic synostosis. However, only two syndromic patients with biallelic variants have been reported in the literature. We report a 4‐year‐old girl with neurodevelopmental delays, dysmorphic features, complex congenital heart disease, renal asymmetry, and arterial tortuosity. Whole exome sequencing showed two homozygous SMAD6 variants of uncertain significance: c.161G>T (p.Gly54Val) and c.1A>G (p.Met1?). This is the third patient with biallelic SMAD6 variants associated with skeletal changes, more complex cardiovascular phenotype, facial dysmorphism, and novel arterial abnormalities. This suggests biallelic variants may cause a distinct and potentially more severe autosomal recessive syndrome. Functional investigation is needed to determine the molecular consequences of biallelic SMAD6 variants and to inform variant classification and mechanism. This report characterizes a potential unique genetic syndrome associated with biallelic SMAD6 variants, highlighting the importance of additional sequencing, vascular imaging, and multidisciplinary care coordination for these patients.
- Open Access
- 11 August 2026
- Published by Springer Nature in Maternal Health, Neonatology and Perinatology
- Vol. 12 (1) , 38
A novel homozygous variant causing fatal neonatal adenylosuccinate lyase (ADSL) deficiency presenting with respiratory failure and encephalopathy
- 11 August 2026
- Published by Springer Nature in Maternal Health, Neonatology and Perinatology
- Vol. 12 (1) , 38
Open AccessA novel homozygous variant causing fatal neonatal adenylosuccinate lyase (ADSL) deficiency presenting with respiratory failure and encephalopathy
- 17 January 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (4) , 101685
Rare heterozygous de novo variants in RAPGEF2 are associated with a neurodevelopmental disorder
- 17 January 2026
- Published by Elsevier in Genetics in Medicine
- Vol. 28 (4) , 101685
Rare heterozygous de novo variants in RAPGEF2 are associated with a neurodevelopmental disorder
- Open Access
- 31 October 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (18) , E1828-E1832
Pearls & Oy-sters: Delayed Response to Pyridoxine in Pyridoxine-Dependent Epilepsy
Inborn errors of metabolism are a diverse group of genetic disorders including many that cause neonatal-onset epilepsy such as pyridoxine-dependent epilepsy (PDE). PDE occurs secondary to biallelic pathogenic variants in ALDH7A1 and can present with refractory neonatal seizures and status epilepticus. Neonatal seizures and encephalopathy are modifiable with pyridoxine (vitamin B6) supplementation. However, the clinical response to pyridoxine supplementation can be delayed. We present the case of a full-term neonate with PDE in which seizure cessation was seen a few hours after intravenous pyridoxine load, but the improvement in EEG background and level of clinical encephalopathy occurred five days later. We share this case to provide an example in which clinical improvement in PDE was gradual and required continuation of treatment for several days illustrating the necessity of continuing vitamin B6 supplementation in suspected cases until confirmatory genetic testing is obtained or an alternate cause is found.
- 31 October 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (18) , E1828-E1832
Open AccessPearls & Oy-sters: Delayed Response to Pyridoxine in Pyridoxine-Dependent Epilepsy
Inborn errors of metabolism are a diverse group of genetic disorders including many that cause neonatal-onset epilepsy such as pyridoxine-dependent epilepsy (PDE). PDE occurs secondary to biallelic pathogenic variants in ALDH7A1 and can present with refractory neonatal seizures and status epilepticus. Neonatal seizures and encephalopathy are modifiable with pyridoxine (vitamin B6) supplementation. However, the clinical response to pyridoxine supplementation can be delayed. We present the case of a full-term neonate with PDE in which seizure cessation was seen a few hours after intravenous pyridoxine load, but the improvement in EEG background and level of clinical encephalopathy occurred five days later. We share this case to provide an example in which clinical improvement in PDE was gradual and required continuation of treatment for several days illustrating the necessity of continuing vitamin B6 supplementation in suspected cases until confirmatory genetic testing is obtained or an alternate cause is found.
- 19 October 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (1) , 90-99
ALDH1A2‐related disorder: A new genetic syndrome due to alteration of the retinoic acid pathway
Aldehyde Dehydrogenase 1, Family Member A2 (ALDH1A2) is essential for the synthesis of retinoic acid from vitamin A. Studies in model organisms demonstrate a critical role for ALDH1A2 in embryonic development, yet few pathogenic variants are linked to congenital anomalies in humans. We present three siblings with multiple congenital anomaly syndrome linked to biallelic sequence variants in ALDH1A2. The major congenital malformations affecting these children include tetralogy of Fallot, absent thymus, diaphragmatic eventration, and talipes equinovarus. Upper airway anomalies, hypocalcemia, and dysmorphic features are newly reported in this manuscript. In vitro functional validation of variants indicated that substitutions reduced the expression of the enzyme. Our clinical and functional data adds to a recent report of biallelic ALDH1A2 pathogenic variants in two families with a similar constellation of congenital malformations. These findings provide further evidence for an autosomal recessive ALDH1A2‐deficient recognizable malformation syndrome involving the diaphragm, cardiac and musculoskeletal systems.
- 19 October 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (1) , 90-99
ALDH1A2‐related disorder: A new genetic syndrome due to alteration of the retinoic acid pathway
Aldehyde Dehydrogenase 1, Family Member A2 (ALDH1A2) is essential for the synthesis of retinoic acid from vitamin A. Studies in model organisms demonstrate a critical role for ALDH1A2 in embryonic development, yet few pathogenic variants are linked to congenital anomalies in humans. We present three siblings with multiple congenital anomaly syndrome linked to biallelic sequence variants in ALDH1A2. The major congenital malformations affecting these children include tetralogy of Fallot, absent thymus, diaphragmatic eventration, and talipes equinovarus. Upper airway anomalies, hypocalcemia, and dysmorphic features are newly reported in this manuscript. In vitro functional validation of variants indicated that substitutions reduced the expression of the enzyme. Our clinical and functional data adds to a recent report of biallelic ALDH1A2 pathogenic variants in two families with a similar constellation of congenital malformations. These findings provide further evidence for an autosomal recessive ALDH1A2‐deficient recognizable malformation syndrome involving the diaphragm, cardiac and musculoskeletal systems.
- 29 March 2021
- Published by S. Karger AG in Molecular Syndromology
- Vol. 12 (3) , 159-168
Pure Distal 7q Duplication: Describing a Macrocephalic Neurodevelopmental Syndrome, Case Report and Review of the Literature
Pure distal duplications of 7q have rarely been described in the medical literature. The term pure refers to duplications that occur without an accompanying clinically significant deletion. Pure 7q duplications of various segments have previously been reported in the literature; however, pure distal 7q duplications have only been reported in 21 cases. Twenty of these earlier reports described patients who were identified via karyotype and 1 recently by microarray. Cases have also been reported in genomic databases such as DECIPHER and the University of California Santa Cruz genome browser. We have reviewed 7 additional cases with distal 7q duplications from these databases and compared them to 7 previously reported distal 7q duplication cases to uncover common features including global developmental delay, frontal bossing, macrocephaly, seizures, kyphoscoliosis/skeletal anomalies, and microretrognathia/palatal anomalies. In this case, we describe a 4-year-old boy with a 30.8-Mb pure duplication of 7q32.1q36.3. Newly reported features associated with this duplication include intermittent dystonic posturing, increased behavioral irritability, eosinophilic esophagitis, segmental vertebral anomalies, and segmental intermittent limb cyanosis. We highlight the importance of using publicly available databases to describe rare genetic syndromes and to better characterize the features of pure distal 7q duplications and further postulate that duplication of this region represents a recognizable macrocephalic neurodevelopmental syndrome.
- 29 March 2021
- Published by S. Karger AG in Molecular Syndromology
- Vol. 12 (3) , 159-168
Pure Distal 7q Duplication: Describing a Macrocephalic Neurodevelopmental Syndrome, Case Report and Review of the Literature
Pure distal duplications of 7q have rarely been described in the medical literature. The term pure refers to duplications that occur without an accompanying clinically significant deletion. Pure 7q duplications of various segments have previously been reported in the literature; however, pure distal 7q duplications have only been reported in 21 cases. Twenty of these earlier reports described patients who were identified via karyotype and 1 recently by microarray. Cases have also been reported in genomic databases such as DECIPHER and the University of California Santa Cruz genome browser. We have reviewed 7 additional cases with distal 7q duplications from these databases and compared them to 7 previously reported distal 7q duplication cases to uncover common features including global developmental delay, frontal bossing, macrocephaly, seizures, kyphoscoliosis/skeletal anomalies, and microretrognathia/palatal anomalies. In this case, we describe a 4-year-old boy with a 30.8-Mb pure duplication of 7q32.1q36.3. Newly reported features associated with this duplication include intermittent dystonic posturing, increased behavioral irritability, eosinophilic esophagitis, segmental vertebral anomalies, and segmental intermittent limb cyanosis. We highlight the importance of using publicly available databases to describe rare genetic syndromes and to better characterize the features of pure distal 7q duplications and further postulate that duplication of this region represents a recognizable macrocephalic neurodevelopmental syndrome.
- 3 January 2020
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (3) , 425-430
Evidence of GMPPA founder mutation in indigenous Guatemalan population associated with alacrima, achalasia, and mental retardation syndrome
Congenital disorders of glycosylation (CDG) are a heterogeneous group of inborn errors of metabolism mostly causing multisystem disease. In 2013, biallelic mutations in the GMPPA gene were described in association with one such CDG known as alacrima, achalasia, and mental retardation syndrome (AAMR). To date, 18 patients have been reported, nearly all displaying the same pathognomonic triad of symptoms described in the name. This condition shares considerable phenotypic overlap with Triple‐A syndrome caused by biallelic mutations in the AAAS gene; however, AAMR lacks the characteristic adrenocortical findings associated with Triple‐A syndrome. We report three patients from two unrelated families with the same homozygous GMPPA mutation (c.265dup, p.L89fs). Notably, both families reported indigenous Maya‐Mam heritage and originated from the town of Concepción Chiquirichapa in Quezaltenango, Guatemala. Our cases help to expand the AAMR phenotype by outlining dysmorphic features not well described in the prior cases. Additionally, we encourage all providers with patients presenting with this unique triad of symptoms to consider sequencing of the GMPPA gene. Special consideration should be given to families of Guatemalan Maya‐Mam ancestry who may also have this identified founder mutation. Finally, this condition may indeed be underdiagnosed based on a review of the literature.
- 3 January 2020
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (3) , 425-430
Evidence of GMPPA founder mutation in indigenous Guatemalan population associated with alacrima, achalasia, and mental retardation syndrome
Congenital disorders of glycosylation (CDG) are a heterogeneous group of inborn errors of metabolism mostly causing multisystem disease. In 2013, biallelic mutations in the GMPPA gene were described in association with one such CDG known as alacrima, achalasia, and mental retardation syndrome (AAMR). To date, 18 patients have been reported, nearly all displaying the same pathognomonic triad of symptoms described in the name. This condition shares considerable phenotypic overlap with Triple‐A syndrome caused by biallelic mutations in the AAAS gene; however, AAMR lacks the characteristic adrenocortical findings associated with Triple‐A syndrome. We report three patients from two unrelated families with the same homozygous GMPPA mutation (c.265dup, p.L89fs). Notably, both families reported indigenous Maya‐Mam heritage and originated from the town of Concepción Chiquirichapa in Quezaltenango, Guatemala. Our cases help to expand the AAMR phenotype by outlining dysmorphic features not well described in the prior cases. Additionally, we encourage all providers with patients presenting with this unique triad of symptoms to consider sequencing of the GMPPA gene. Special consideration should be given to families of Guatemalan Maya‐Mam ancestry who may also have this identified founder mutation. Finally, this condition may indeed be underdiagnosed based on a review of the literature.
- 12 December 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (3) , 584-590
TFE3‐associated neurodevelopmental disorder: A distinct recognizable syndrome
The transcription factor for immunoglobulin heavy‐chain enhancer 3 (TFE3) gene encodes a transcription factor that regulates embryonic stem cell (ESC) differentiation. Its phosphorylation by the lysosomal Rag GTPase signaling pathway leads to cytoplasmic sequestration and inactivation promoting ESC differentiation and exit from pluripotency. Somatic translocations of this X‐linked gene cause papillary renal cell carcinoma in which nuclear accumulation of the TFE3 oncoprotein is one of the most significant histopathologic characteristics. Early this year, Villegas et al. identified missense mutations in a TFE3 domain required for cytoplasmic inactivation as potentially causal for a mosaic human developmental disorder. They published five patients with de novo TFE3 nonsynonymous missense variants, four females and one male, with severe intellectual disability (5/5), coarse facial features (4/5), and Blaschkoid pigmentary mosaicism (4/5). The only male described has somatic mosaicism. All patients had normal brain Magnetic Resonance Imagings (MRIs). We present two unrelated females with this distinctive phenotype including the above triad along with other features not previously well described. Both were found to have de novo heterozygous variants in TFE3 on whole exome sequencing, one nonsynonymous missense, and one canonical splice site variant, thereby expanding the phenotypic and mutational spectrum for this disorder. Interestingly, due to significant coarsening of the facial features, both patients were initially thought to have a lysosomal storage disorder but enzyme screening and brain MRIs were negative.
- 12 December 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (3) , 584-590
TFE3‐associated neurodevelopmental disorder: A distinct recognizable syndrome
The transcription factor for immunoglobulin heavy‐chain enhancer 3 (TFE3) gene encodes a transcription factor that regulates embryonic stem cell (ESC) differentiation. Its phosphorylation by the lysosomal Rag GTPase signaling pathway leads to cytoplasmic sequestration and inactivation promoting ESC differentiation and exit from pluripotency. Somatic translocations of this X‐linked gene cause papillary renal cell carcinoma in which nuclear accumulation of the TFE3 oncoprotein is one of the most significant histopathologic characteristics. Early this year, Villegas et al. identified missense mutations in a TFE3 domain required for cytoplasmic inactivation as potentially causal for a mosaic human developmental disorder. They published five patients with de novo TFE3 nonsynonymous missense variants, four females and one male, with severe intellectual disability (5/5), coarse facial features (4/5), and Blaschkoid pigmentary mosaicism (4/5). The only male described has somatic mosaicism. All patients had normal brain Magnetic Resonance Imagings (MRIs). We present two unrelated females with this distinctive phenotype including the above triad along with other features not previously well described. Both were found to have de novo heterozygous variants in TFE3 on whole exome sequencing, one nonsynonymous missense, and one canonical splice site variant, thereby expanding the phenotypic and mutational spectrum for this disorder. Interestingly, due to significant coarsening of the facial features, both patients were initially thought to have a lysosomal storage disorder but enzyme screening and brain MRIs were negative.